Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Heart Diseases 3Vascular Diseases 2Small Cell Lung Carcinoma 2Cardiovascular Diseases 2Cardiotoxicity 2Triple Negative Breast Neoplasms 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Cancer Resectable 1Ovarian Carcinosarcoma 1Neoplasms, Second Primary 1Myelodysplastic Syndromes 1Metabolic Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Immune-related Adverse Event 1Hematologic Neoplasms 1Heart Failure 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Hepatocellular 1Cancer Therapy-related Cardiovascular Toxicity 1Breast Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Radiotherapy 2Radiosurgery 2Leucovorin 2Irinotecan 2Fluorouracil 2Drug Therapy 2sacubitril and valsartan sodium hydrate drug combination 1icotinib 1dostarlimab 1beta Carotene 1avelumab 1alpha-Tocopherol 1Varenicline 1Tyrosine Kinase Inhibitors 1Trastuzumab 1Tobacco Use Cessation Devices 1Therapeutics 1Thalidomide 1Temozolomide 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Semen Analysis 1Registries 1Probiotics 1Patient Reported Outcome Measures 1Panitumumab 1Nicotine Chewing Gum 1Myofascial Release Therapy 1Megestrol Acetate 1Isotretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Second Primary × Antineoplastic Agents × Clear all
NCT03777930 2018-12-19

The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol

Shenzhen Fifth People's Hospital

Phase 4 Unknown
200 enrolled
Tumor-Agnostic

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡